|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Prothrombin Mutation
Test CodePROTHROMBIN MUT. (WH)
Alias/See Also
Factor II Mutation
Prothrombin 20210A Mutation
G20210A Mutation
Prothrombin 20210A Mutation
G20210A Mutation
Preferred Specimen
Whole blood lavender EDTA
Instructions
Do not centrifuge or freeze
Transport Temperature
Refrigerate (2-8°C)
Methodology
Roche Light Cycler – Melting Curve Analysis - LDT
This test was developed and its performance characteristics determined by the VACT Healthcare System. It has not been cleared or approved by the FDA. Such approval is not necessary. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988(CLIA-88) as qualified to perform high complexity clinical laboratory testing.
Setup Schedule
Once per week
Report Available
8 Days
Reference Range
Homozygous Normal (Wild-Type)
Clinical Significance
The Factor II (Prothrombin) G20210A test is an in vitro diagnostic test for the detection and genotyping of the Factor II (Prothrombin) G20210A mutation as an aid to diagnosis in the evaluation of patients with suspected thrombophilia.
Inherited thrombophilia predisposes an individual to thrombotic events such as venous thrombosis, the third most common cardiovascular disease . Activated protein C (APC) resistance is regarded as the most prevalent coagulation abnormality associated with venous thrombosis. Patients testing positive for APC resistance or the Factor V Leiden mutation should be considered for molecular genetic testing for the other most common thrombophilias with overlapping phenotype, for which testing is available at present [i.e., the Factor II (Prothrombin) G20210A variant] whichis present in 1–2% of the general population and its involvement in venous thromboembolism is well established.
Inherited thrombophilia predisposes an individual to thrombotic events such as venous thrombosis, the third most common cardiovascular disease . Activated protein C (APC) resistance is regarded as the most prevalent coagulation abnormality associated with venous thrombosis. Patients testing positive for APC resistance or the Factor V Leiden mutation should be considered for molecular genetic testing for the other most common thrombophilias with overlapping phenotype, for which testing is available at present [i.e., the Factor II (Prothrombin) G20210A variant] whichis present in 1–2% of the general population and its involvement in venous thromboembolism is well established.
Performing Laboratory
Test performed at the VA Connecticut Molecular Diagnostics Laboratory
Contact: Jacqueline Dang 203-932-5711
Ext: 2915/2919
Fax: 203-937-4786
Last Updated: October 28, 2015
